Abaloparatide

(Tymlos®)

Abaloparatide

Drug updated on 11/14/2023

Dosage FormInjection (subcutaneous: 3120 mcg/1.56 mL)
Drug ClassHuman parathyroid hormone related peptide analogs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of postmenopausal women with osteoporosis at high risk for fracture.